Flerie Q3 net loss more than doubles to SEK 281 million
Flerie’s net loss more than doubled to SEK 281 million in its January—September 2026 interim report. Net asset value fell 21% year over year to SEK 3.11 billion; portfolio shares’ total fair value dropped 12% to SEK 2.73 billion. During the quarter, portfolio company Empros Pharma’s net asset value was written down in full. Shareholders approved the Biosergen merger plan, with completion expected in October. Egetis Therapeutics received FDA approval for EMCITATE; Xspray Pharma received an FDA complete response letter for Dasynoc. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Flerie AB published the original content used to generate this news brief on October 15, 2026, and is solely responsible for the information contained therein. (C)
Flerie’s net loss more than doubled to SEK 281 million in its January—September 2026 interim report. 73 billion. During the quarter, portfolio company Empros Pharma’s net asset value was written down in full. Shareholders approved the Biosergen merger plan, with completion expected in October.
Egetis Therapeutics received FDA approval for EMCITATE; Xspray Pharma received an FDA complete response letter for Dasynoc. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Flerie AB published the original content used to generate this news brief on October 15, 2026, and is solely responsible for the information contained therein.
(C)